Meeting
2011 ASCO Annual Meeting
Correlation between miRNA and gene expression profiles and response to neoadjuvant chemotherapy in patients with locally advanced and inflammatory breast cancer.
Authors
G. Somlo
City of Hope, Duarte, CA
G. Somlo , S. M. Li , X. Wu , S. Lau , P. H. Frankel , L. Kruper , H. Gao , G. Sun , J. H. Yim , A. Hurria , J. E. Mortimer , F. De Snoo , I. B. Paz , J. Rossi , E. Wang , P. Roepman , Y. Yen , L. van't Veer , R. A. Bender
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT00295893
Citation
J Clin Oncol 29: 2011 (suppl; abstr 548)
Abstract #
548
Poster Bd #
2E
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Correlation between miRNA (miR) and gene expression profiles (GEP) and response to neoadjuvant chemotherapy (NT) in patients with locally advanced and inflammatory breast cancer (BC).
First Author: Sierra Mi Li
Poster
2015 Breast Cancer Symposium
Pathologic complete response after neoadjuvant paclitaxel and carboplatin chemotherapy for stage II-III breast cancer: A community cancer center experience.
First Author: Anuradha Belur
Poster
2015 ASCO Annual Meeting
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer.
First Author: Naoko Matsuda
Poster
2012 Breast Cancer Symposium
Metronomic chemotherapy (MC) in the neoadjuvant setting: Results of two parallel feasibility trials in patients (pts) with HER2 positive (HER2+) and negative (HER2-) locally advanced breast cancer (LABC) (Traq-Me and TAME).
First Author: Vanessa Petry